Literature DB >> 15316000

Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome.

Henry C Lin1.   

Abstract

CONTEXT: Irritable bowel syndrome (IBS), which affects 11% to 14% of the population, is a puzzling condition with multiple models of pathophysiology including altered motility, visceral hypersensitivity, abnormal brain-gut interaction, autonomic dysfunction, and immune activation. Although no conceptual framework accounts for all the symptoms and observations in IBS, a unifying explanation may exist since 92% of these patients share the symptom of bloating regardless of their predominant complaint. EVIDENCE ACQUISITION: Ovid MEDLINE was searched through May 2004 for relevant English-language articles beginning with those related to bloating, gas, and IBS. Bibliographies of pertinent articles and books were also scanned for additional suitable citations. EVIDENCE SYNTHESIS: The possibility that small intestinal bacterial overgrowth (SIBO) may explain bloating in IBS is supported by greater total hydrogen excretion after lactulose ingestion, a correlation between the pattern of bowel movement and the type of excreted gas, a prevalence of abnormal lactulose breath test in 84% of IBS patients, and a 75% improvement of IBS symptoms after eradication of SIBO. Altered gastrointestinal motility and sensation, changed activity of the central nervous system, and increased sympathetic drive and immune activation may be understood as consequences of the host response to SIBO.
CONCLUSIONS: The gastrointestinal and immune effects of SIBO provide a possible unifying framework for understanding frequent observations in IBS, including postprandial bloating and distension, altered motility, visceral hypersensitivity, abnormal brain-gut interaction, autonomic dysfunction, and immune activation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15316000     DOI: 10.1001/jama.292.7.852

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  96 in total

1.  Case studies of antibiotic therapy in the management of functional gastrointestinal disorders.

Authors:  Mark Pimentel; Charles Cattano; Jennifer Christie; Charles Loewe; Venkat Mohan
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-01

2.  The Treatment of Patients With Irritable Bowel Syndrome: Review of the Latest Data From the 2010 DDW Meeting.

Authors:  Mark Pimentel
Journal:  Gastroenterol Hepatol (N Y)       Date:  2010-07

3.  Use of probiotics in gastrointestinal disorders: what to recommend?

Authors:  Elizabeth C Verna; Susan Lucak
Journal:  Therap Adv Gastroenterol       Date:  2010-09       Impact factor: 4.409

Review 4.  Irritable bowel syndrome and functional dyspepsia: different diseases or a single disorder with different manifestations?

Authors:  Laura Noddin; Michael Callahan; Brian E Lacy
Journal:  MedGenMed       Date:  2005-08-29

Review 5.  Evaluation of lower functional gut disorders.

Authors:  Christopher N Andrews; Martin Storr
Journal:  Can J Gastroenterol       Date:  2008-07       Impact factor: 3.522

6.  Gastrointestinal bacterial overgrowth: pathogenesis and clinical significance.

Authors:  Amit H Sachdev; Mark Pimentel
Journal:  Ther Adv Chronic Dis       Date:  2013-09       Impact factor: 5.091

7.  Immune activation and gut microbes in irritable bowel syndrome.

Authors:  Khaldun Al-Khatib; Henry C Lin
Journal:  Gut Liver       Date:  2009-03-31       Impact factor: 4.519

8.  Rifaximin: recent advances in gastroenterology and hepatology.

Authors:  Gary R Lichtenstein
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-06

9.  Chronic diarrhea in travelers.

Authors:  Bradley A Connor
Journal:  Curr Infect Dis Rep       Date:  2013-06       Impact factor: 3.725

10.  Increased risk for irritable bowel syndrome after acute diverticulitis.

Authors:  Erica Cohen; Garth Fuller; Roger Bolus; Rusha Modi; Michelle Vu; Kamyar Shahedi; Rena Shah; Mary Atia; Nicole Kurzbard; Victoria Sheen; Nikhil Agarwal; Marc Kaneshiro; Linnette Yen; Paul Hodgkins; M Haim Erder; Brennan Spiegel
Journal:  Clin Gastroenterol Hepatol       Date:  2013-03-21       Impact factor: 11.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.